INTRODUCTION
============

NATURAL ANTIMICROBIAL PEPTIDES: SOLDIERS IN THE BODY'S FIRST LINE OF DEFENSE
----------------------------------------------------------------------------

Once the organism is invaded by a pathogen, a primary response from the host immune system comprises production of specific peptides as defense compounds. Several of these humoral response peptides exert antibacterial, antifungal, or antiviral properties ([@B23]) and are known as host defense peptides, or antimicrobial peptides (AMP; [@B12]). Hence, AMP form the first line of host defense against infection and are a key component of the ancient innate immune system. Most AMP are small amphipathic peptides, usually with 15--45 amino acid (AA) residues, and, in general, are cationic at physiological pH ([@B19]).

Antimicrobial peptides, which may be encoded by separate genes or produced by non-ribosomal biosynthesis, have been identified in various species from bacteria to insects, amphibians to mammals, including humans ([@B150]; [@B104]). In insects, AMP are synthesized in the fat body, in hemocytes, or epithelia, and are released into the hemolymph. In vertebrates, AMP are present in amphibian skin secretions ([@B121]) and epithelia ([@B52]; [@B7]); in mammals, AMP are also observed in lymphocytes ([@B2]) and leukocytes ([@B124]).

Because of their broad activity against microbes, and their expression triggered by various infections, AMP have been intensely examined as potential therapeutic agents ([@B150]). In 2004, the antimicrobial peptide database (APD, <http://aps.unmc.edu/AP/main.php>), created at the University of Nebraska Medical Center, already gathered a significant number of AMP that had been discovered at both the gene and protein levels ([@B138]). Later, APD has been updated and expanded to a second version that allows users to search peptides by families (e.g., bacteriocins, cyclotides, or defensins), sources (e.g., fish, frogs, or chicken), post-translational modifications (e.g., amidation, oxidation, lipidation, glycosylation, or inclusion of D-AA), and binding targets \[e.g., cell membranes, proteins, nucleic acids, lipopolysaccharides (LPSs), or other sugars; [@B136]\]. Today, there is a huge plethora of AMP of both natural and synthetic origin, as recently reviewed elsewhere ([@B123]; [@B117]; [@B77]; [@B112]; [@B120]), highlighting AMP as relevant antibiotics ([@B48]).

ORGANIZING DIVERSITY: STRUCTURE-BASED CLASSIFICATION OF ANTIMICROBIAL PEPTIDES
------------------------------------------------------------------------------

The diversity of AMP reported since earlier disclosures in this area has soon made clear that some organization/classification of AMP families was needed. For instance, [@B19] proposed AMP to be split into three major groups: (a) linear α-helical peptides free of cysteine residues; (b) β-pleated peptides containing disulfide bridges; (c) peptides with an overrepresentation of certain AA, such as proline, arginine, tryptophan, or histidine. However, peptides that did not fit into any of these groups were later found to be antimicrobial, as is the case of circular peptides like θ-defensins ([@B87]) or cyclotides ([@B65]). Hence, at present, four main types of AMP can be roughly distinguished:

### α-helical peptides deprived of Cys residues

Linear cationic α-helical AMP are a class of small peptides whose charge is imparted by the presence of multiple Lys and Arg, but also with a substantial portion (50% or more) of hydrophobic residues. These peptides are known for their broad-spectrum antimicrobial activity and ability to modulate the innate immune response ([@B109]). One example is that of melittin, an α-helical cationic peptide from the venom of *Apis mellifera* bees, composed of 26 AA residues and in which the amino-terminal region is predominantly hydrophobic whereas the carboxy-terminal region is hydrophilic due to the presence of a stretch of positively charged AA ([@B113]). Melittin is a potent antimicrobial that seems to promote membrane permeabilization through pore formation according to the toroidal model ([@B146]). However, its hemolytic activity is too high for clinical application as a selective AMP, which led to studies addressing synthesis and evaluation of the antimicrobial potential of hybrid peptide constructs where melittin (entire or partial AA sequence) was combined with other non-hemolytic AMP, such as cecropins ([@B20]; [@B8]; [@B90]). Cecropins constitute a well-known family of α-helical AMP that share a similar structure containing two α-helical domains linked by a flexible region. Insect cecropins are known to induce pore formation in negatively-charged bacterial membranes ([@B47]; [@B126]). In turn, a positive surface charge or cholesterol present in the membrane bilayer decreases the channel formation potency of cecropins ([@B29]), which explains why these have little or no effect on eukaryotic cells (being non-hemolytic) that are richer in zwitterionic phospholipids and contain a high amount of cholesterol as compared to bacteria ([@B147]; [@B11]; [@B110]).

Other widely studied families of α-helical, linear and cysteine-free AMP are those of magainins and dermaseptins, both naturally occurring in amphibians. Magainins 1 and 2 adopt an α-helical conformation in solution ([@B149]), and have been proposed to induce toroidal pores in bacterial membranes ([@B94]). The non-hemolytic character of magainin 2 and its protocidal activity underlie its interest as a potential anti-parasitic agent, and also as a template for creation of more potent large spectrum AMP analogs, such as pexiganan ([@B55]). In what concerns peptides from the dermaseptin super-family, these exhibit a broad range of antimicrobial activity and some of them were found to aggregate on the bacterial membrane surface in a carpet-like manner ([@B108]).

### β-pleated peptides containing disulfide bridges

A classical example of this group of AMP is that of defensins, peptides mostly found in mammalian phagocytes that usually contain six Cys residues (eight Cys have been found in some insect defensins) stabilizing peptide structure by forming three intramolecular disulfide bridges ([@B119]). The mechanism of action of these peptides seems to also involve pore formation inducing membrane permeabilization, which is more extensive on negatively charged phospholipid bilayers ([@B86]; [@B145]).

### Peptides rich in Pro, Gly, His, Arg, and Trp residues

This is a somewhat more heterogeneous group of AMP, as those included are diverse in sequence and tridimensional structure, sharing the feature of having an overrepresentation of certain AA, specifically, Pro, Gly, His, Arg, and Trp. From this follows that AMP of this group seem to also have diverse mechanisms of antimicrobial action, in some cases apparently involving intracellular targets ([@B103]).

A family of Pro-rich AMP is that of apidaecins, short peptides that may adopt a polyproline type II helical structure which could be the structural basis to bind to specific targets underlying its antibacterial activity ([@B88]). In fact, apidaecins do not seem to interact with microbial membranes through formation of pores, but rather by an energy-driven, eventually transporter-mediated, process ([@B28]).

Gly-rich AMP have been found with variable sizes and without any clear sequence signature, apart from the high proportion (25--50%) of glycine residues. These peptides are in general longer than AMP from other classes, have disordered structure in water, and tend to self-order when in contact with artificial membranes ([@B22]). Attacins are family of six Gly-rich AMP that can be divided into four basic (A--D) and two acidic (E--F) peptides, probably derived from two attacin genes ([@B148]). Attacins inhibit the synthesis of outer membrane proteins of *Escherichia coli* by blocking transcription of the respective genes ([@B25]), which is presumably achieved by an indirect mechanism, since attacins bind to the bacterial LPS but do not need to enter the cell to exert their action ([@B26]).

Tryptophan-rich AMP contain more than 25% of this amino acid. In what concerns this class of AMP, the archetypical example is that of indolicin, which adopts no particular secondary structure in water, but seems to undergo significant structural changes in the vicinity of lipid bilayers, explaining its strong membrane affinity underlying its antimicrobial activity ([@B78]). This peptide has the ability to permeate bacterial membranes and, depending of its tridimensional shape, inhibits DNA synthesis by binding to it ([@B63]). Other examples of Trp-rich AMP include tritrpticin ([@B80]), lactoferricin B ([@B14]), and Pac-525 ([@B140]).

His-rich AMP usually have 25% of their AA content represented by His. In general, these peptides show a cationic amphipathic helical structure, and trigger microbial membrane disruption when adopting an alignment parallel to the membrane surface. Still, pore formation is not essential for the high antimicrobial activity of many His-rich AMP ([@B98]). Clavanin ([@B130]), daptomycin ([@B67]), LAH4 ([@B9]), or D-HALO-rev ([@B98]) are a few examples of this class of AMP.

### Circular antimicrobial peptides

Discovery of antimicrobial activity on natural cyclic peptides that did not fit any of the previous three groups justifies the need to consider a fourth group, dedicated to circular AMP. θ-defensins, for instance, fit this group: they are cyclic octadecamers active against several Gram-positive and Gram-negative bacteria, fungi, and some viruses, which consist of a couple of antiparallel β-sheets linked by three disulfide bonds to produce a very stable structure ([@B87]). Some bacteriocins, which are polypeptide toxins produced by bacteria to inhibit the growth of competing bacterial species or strain(s) ([@B35]), are also circular AMP; that is the case of AS-48, a cyclic 70-mer bacteriocin from *Enterococcus faecalis*, possessing an overall globular structure where five α-helices enclose a dense hydrophobic core ([@B59]). Finally, one of the most emblematic families of circular AMP is that of cyclotides ([@B65]): these are plant-derived peptides, with approximately 30 AA, characterized by a head-to-tail cyclic backbone and three or four disulfide bonds forming the so-called cyclic cysteine knot (CCK; [@B37]), for which they are also known as "knotted peptides." As a result of their singular structure, these peptides are extremely stable, retaining their biological activity after boiling and being extremely resistant to enzymatic degradation ([@B132]; [@B36]).

ANTIMICROBIAL PEPTIDES: A NEW SOLUTION AGAINST MALARIA?
=======================================================

A MILLENARY WORLDWIDE DISEASE STILL FAR FROM ERADICATION
--------------------------------------------------------

Human malaria is caused by any of five species of protozoal, apicomplexan parasites of the genus *Plasmodium*, *P. vivax*, *P. ovale*, *P. malariae*, *P. knowlesi,* and *P. falciparum*, the latter being the most virulent, the best characterized, and (along with *P. vivax*) the most widespread species. Rodent malaria parasites such as *P. berghei* and *P. yoelii*, the avian parasite *P. gallinaceum*, or the human parasite *P. falciparum* are the most well-studied and used to evaluate drug-parasite interactions ([@B111]; [@B42]; [@B97]; [@B114]). Parasites of the *Apicomplexa* are important animal pathogens notable for their complex life cycles and highly specialized invasive forms. Besides *Plasmodia*, apicomplexan parasites include the agents of toxoplasmosis, cryptosporidiosis, and several other significant parasitic diseases ([@B143]; [@B122]).

The definitive host of *Plasmodia*, the female *Anopheles* mosquito, transmits the infective forms of the parasite, sporozoites, to the intermediate host (usually, a mammal) during its blood meal. After migration to the liver, the parasites develop within hepatocytes, of which they later exit as merozoites that are released into the bloodstream. Inside red blood cells (RBC) the asexual lifecycle takes place, starting by merozoite development into the ring stage, this in turn evolves to produce metabolically highly active trophozoites, which finally give place to schizonts, responsible for the release of new merozoites to infect other healthy RBC. Occasionally, ring forms can also develop into female and male gametocytes that, once ingested by another *Anopheles* mosquito, start the sexual lifecycle by developing into ookinetes, oocysts, and finally sporozoites, which migrate into the salivary gland to be transferred to another host on the following blood meal (**Figure [1](#F1){ref-type="fig"}**).

![**Life cycle of malaria parasite.** Malaria transmission occurs through a vector, the female *Anopheles* mosquito, which ingests gametocytes (the only infective form to mosquitoes) when feeding on infected blood (adapted with permission from [@B72]).](fphar-05-00275-g001){#F1}

The complex life-cycle of malaria parasites, and the ease at which these undergo mutations to escape drug pressure, are the major factors behind both the limitations of current control methods and the urgent need for new chemoprophylactic and chemotherapeutic agents. These aspects have been comprehensively discussed elsewhere ([@B105]; [@B127]), turning clear that, while antimalarial drugs in use (mostly artemisinin and derivatives, quinolines or related compounds, and inhibitors of the folate pathway) can be effective in many situations, improvements in terms of (especially) cost and safety are highly desirable ([@B49]; [@B133]; [@B142]). Yet, this is a difficult endeavor, as the mechanisms of action of many antimalarial drugs are still poorly understood. For instance, the current first-line antimalarial drugs, artemisinin and related compounds, have been suggested to eliminate the Ca^2+^-dependent ATPase activity of P*f*ATP6 ([@B44]); however, other modes of action have been attributed to this family of antimalarials as, e.g., binding to ferriprotoporphyrin IX (a by-product of hemoglobin degradation), free radical-mediated damage or interference with hematin polymerization and detoxification ([@B115]; [@B15]). Other antimalarial drugs seem to target the redox systems of *Plasmodia*, whose survival is highly dependent on the antioxidative stress system of their hosts ([@B10]). An example is that of chloroquine, formerly used as first-line treatment for uncomplicated malaria, which inhibits polymerization of toxic heme (Fe^2+^) into hemozoin inside the parasite's food vacuole ([@B125]). Primaquine, which remains the only transmission-blocking anti-malarial clinically available worldwide, seems to equally target the parasite's redox system; this drug displays marked activity against gametocytes of all species of human malaria, including multi-resistant *P. falciparum* strains, and is also effective against all exoerythrocytic forms of the parasite, including hypnozoites, dormant liver forms responsible for relapse of *vivax* and *ovale* malaria. Unfortunately, as many other clinically relevant antimalarials, primaquine is often associated with serious adverse effects, in consequence of its toxic metabolites ([@B129]).

Another drawback in antimalarial containment has emerged from misuse of available drugs, and marketing of fake ones, leading to widespread resistance. This has been the major factor behind chloroquine's loss of prominence in the antimalarial arsenal from the 1980s onward, and is also becoming a cause of concern regarding 21st century first-line artemisinin-based combination therapies (ACT): the first signs of plasmodial resistance to artemisinin emerged in Southeast Asia in 2008 ([@B43]).

The above explains why malaria eradication is still out of reach and why the need to feed the antimalarial drug pipeline remains an urgent problem. In this connection, membrane-active peptides (MAP), such as most AMP, may offer interesting solutions, as by having cell membranes as their primary targets, their action will be harder to fight back by malaria parasites.

ANTIMICROBIAL PEPTIDES WITH ANTIMALARIAL PROPERTIES
---------------------------------------------------

There have been numerous reports on peptides active against various cultured stages of malaria parasites and/or in animal models of malaria. The range of size, AA composition, and secondary structure of such peptides is impressive, going from dipeptides up to polypeptides large enough to be considered as proteins. Antimalarial activity has been described for several substrate analogs of different plasmodial peptidases involved in host hemoglobin degradation, host-cell invasion and egress, and intracellular housekeeping ([@B16]; [@B139]). One interesting example is that of the ankyrin peptide (AnkP), a potent inhibitor of the major cysteine protease of *P. falciparum*, falcipain-2, which was delivered into parasite-infected red blood cells (*Pf*RBC) via the *Antennapedia* homeoprotein internalization domain; this served to demonstrate not only the antimalarial properties of peptidase substrate analogs like AnkP, but also the potentially useful role of another class of MAP, the cell-penetrating peptides/proteins (CPP), for intracellular delivery of antimalarials ([@B41]). There have been also many reports on synthetic peptides or protein fragments with specific targets at parasite/host or parasite/vector interfaces, for instance, peptide fragments of adhesins that are involved in host-cell invasion ([@B96]).

Many broad-spectrum AMP from various sources, including anopheline mosquitoes (malaria vectors), have also been found to exhibit different degrees of antimalarial action ([@B12]). The fact that *Plasmodia* are eukaryotes may appear incompatible with the general notion that selective AMP preferentially target negatively-charged prokaryote membranes; however, the phospholipid composition of membranes from intraerythrocytic parasites are markedly different from those of their host eukaryote cells, RBC; moreover, upon infection by *P. falciparum*, RBC undergo significant changes in their membranes, whose composition gets closer to that of parasitic membranes ([@B62]). For instance, as compared to healthy RBC, *Pf*RBC have increased contents of phosphatidylinositol and phosphatidic acid, and decreased contents of sphingomyelin, whereas phosphatidylethanolamines remain more or less unchanged ([@B62]). In other words, *Pf*RBC membranes differ from those of healthy RBC; this, together with the fact that mechanisms of antimalarial action by AMP remain unknown, explains why the paradox of AMP exhibiting antiprotozoal action is only apparent. This comes in agreement with findings from [@B56], who found that NK-2, a small cationic AMP, while hardly affecting healthy RBC, promptly internalized *Pf*RBC, affecting the viability of intracellular parasites; studies with liposomes, by the same authors, revealed a phosphatidylserine-dependent lysis by NK-2, which indicates that small cationic AMP may be selective to *Pf*RBC, hence, emerging as a potential new class of antimalarials. In fact, a range of natural and synthetic AMP were found to have promising anti-plasmodial properties (**Table [1](#T1){ref-type="table"}**), showing that modulation of the innate immune response is an effective approach to novel peptide anti-infective agents ([@B61]). Another relevant example is that of phylloseptin-1(PS-1), an AMP capable to control the growth and cause *in vitro* destruction of *P. falciparum*, at the concentration of 16 μg/mL, well-below the levels at which this peptide is toxic to mammalian cells ([@B75]). More examples of antimalarial AMP are next revised in higher detail.

###### 

Antimicrobial peptides reported as active against *Plasmodium spp*. parasites.

  Peptide                    Sequence/origin/reference                                                                                            Activity
  -------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  CA(1-13)M(1-13)            KWKLFKKIEKVGQGIGAVLKVLTTGL Cecropin A/melittin hybrid ([@B51])                                                       IC~50~ 10 mM (*Pf*RBC)
  Cecropin B                 KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG *Hyalophora cecropia* ([@B60])                                                  81--94% abortion of oocyst development (*Plasmodium spp.*) at 0.5 μg/μL (128 μM)
  Defensin A                 ATCDLLSGFGVGDSACAAHCIARGNRGGYCNSKKVCVCRN *Aedes aegypti* ([@B73])                                                    ∼85% inhibition of oocyst proliferation in transgenic mosquitoes (*P. gallinaceum*)
  Dermaseptin DS~3~          *X-*ALWKNMLKGIGKLAGKAALGAVKKLVGAES *Phyllomedusa sauvagii* (dermaseptin derivative) ([@B57])                         IC~50~ 0.8--1.5 μM (*Pf*RBC)
  Dermaseptin DS~4~          *X-*ALWMTLLKKVLKAAAKAALNAVLVGANA *Phyllomedusa sauvagii* (dermaseptin derivative) ([@B57])                           IC~50~ 0.27--2.2 μM (*Pf*RBC)
  D -HALO-rev                AKKLOHALHOALLALOHLAHOLLAKK *Synthetic* ([@B98])                                                                      IC~50~ 0.1 μM (*Pf*RBC)
  Drosomycin                 DCLSGRYKGPCAVWDNETCRRVCKEEGRSSGHCSPSLKC-WCEGC *Drosophila melanogaster* ( [@B128])                                   70% gametocytes inhibition at 20 μM (*P. berghei*)
  Gambicin                   MVFAYAPTXARXKSIGARYXGYGYLNRKGVSXDGQTTIN-SXEDXKRKFGRXSDGFIT *Anopheles gambiae* ( [@B135])                            54.6% ookinetes killed at 10 μM (*P. berghei*)
  IDR-1018                   VRLIVAVRIWRR Bactenicin derivative (bovine neutrophils) ( [@B144])                                                   Protection against cerebral malaria
  Dermaseptin K4K20-S4       ALWKTLLKKVLKAAAKAALKAVLVGANA *Phyllomedusa sauvagii* (dermasepin S4 derivative) ([@B74])                             IC~50~ 0.2 μM (*Pf*RBC)
  Dermaseptin K4-S4(1-13)a   ALWMTLLKKVLKA *Phyllomedusa sauvagii* (Dermasepin S4 derivative) ([@B74])                                            IC~50~ 6 mM (*Pf*RBC)
  Dermaseptin NC7-P          H~2~N-(CH~2~)~6~-CO-ALWKTLLKKVLKA-NH~2~ *Phyllomedusa sauvagii* (dermaseptin K4-S4(1-13)a derivative) ([@B46])       IC~50~ 5.3 μM (*Pf*RBC, ring stage); 6.2 μM (*Pf*RBC, trophozoites)
  Magainin 2                 GIGKFLHSAKKFGKAFVGEIMNS *Xenopus laevis* ([@B51])                                                                    82--95% abortion ofoocyst development (*Plasmodium spp.*) at 0.5 μg/mL (203 μM)
  NK-2                       KILRGVCKKIMRTFLRRISKDILTGKK Synthetic ([@B56])                                                                       IC~50~ 1--10 μM (*Pf*RBC)
  SB-37                      MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG Synthetic cecropin B derivative ([@B66])                                      IC~50~ ∼50 μM (*Pf*RBC)
  Scorpine                   GWINEEKIQKKIDERMGNTVLGGMAKAIVHKMAKNEFQ-CMANMDMLGNCEKHCQTSGEKGYCHGTKCKCGTPLSY *Pandinus imperator* ([@B33]; [@B24])   IC~50~: 1 μM (*P. berghei* ookinetes); ∼10 μM (*P. berghei* gametes)
  Shiva-1                    MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG Synthetic cecropin B derivative ([@B66])                                      IC~50~ ∼20 μM (*Pf*RBC)
  Vida1 Vida 2 Vida 3        KWKKFKKGIGKLFV KWPKFKKGIPWLFV KWPKFRRGIPFLFV Synthetic cecropin B/melittin hybrids ([@B6])                           ≥60% mortality of young *P. berghei* ookinetes at 50 μM

### Cecropins and derivatives

Cecropins, from the moth *Hyalophora cecropia*, disturb the development of oocysts into sporozoites, with a 50% lethal dose between 0.5 and 1 μg/μL ([@B60]). Synthetic derivatives of cecropins have also been produced and analyzed for their effects against malaria: SB-37, highly similar to cecropin B, and Shiva-1, with 40% homology to the same cecropin from *H. cecropia*, were significantly lytic to *P. falciparum* blood stage forms at 50 μM; still, while SB-37 was equipotent to cecropin B, Shiva-1 was twice as active as this cecropin ([@B66]). The effect of another cecropin-like peptide, Shiva-3, on *in vitro* ookinete development and on the early sporogonic stages of *P. berghei* in the midgut of *Anopheles albimanus* mosquitoes was investigated; peptide concentrations of 75 and 100 μM were effective in reducing ookinete production and the number of infected mosquitoes in almost all experiments ([@B116]).

Hybrids of non-hemolytic cecropins with the potent bee venom toxin melittin have been found to inhibit RBC re-invasion by *P. falciparum*; an example of one such hybrid is that of CA(1-13)M(1-13), which is an order of magnitude more potent than magainin, cecropin A, and cecropin B, and is active in the 5--10 μM range ([@B51]). More recent cecropin-melittin hybrids Vida1 (mainly consisting of α-helices), Vida2 (essentially composed by β-sheets), and Vida3 (a combination of coils and sheets) were developed and tested against *P. berghei* and *P. yoelii* gametocytes. The mortality rate of: Vida1 was 65% on young ookinetes (10 h), Vida2 was 60--70% on maturing ookinetes (14 and 24 h), and Vida3 was higher than 60% throughout the entire developmental period ([@B6]). The antimalarial activity of Vida3 was associated to blockage of *Plasmodium* oocyst development, and the peptide was further found as toxic to *Anopheles gambiae* cells at 25 μM ([@B27]).

The exact molecular mechanisms of membrane activity of cecropins have been under debate for more than 30 years, with two general models being proposed: formation of transmembrane pores, and the carpet model ([@B101]). A recent study demonstrates that cecropins A and B produce well-defined ion channels of different conductance levels in bilayer lipid membranes; further increase in peptide concentration causes destabilization and subsequent breakdown of the bilayer, showing that formation of pores is a first stage of membrane destabilization by these two cecropins, while accumulation of a dense peptide carpet precedes complete bilayer disintegration ([@B45]).

### Amphibian antimalarial peptides: dermaseptins, magainins

Dermaseptins, from the skin of *Phyllomedusa* frogs, are highly active against intraerythrocytic forms of different *P. falciparum* strains, with IC~50~ values between 0.8 and 2.2 μM ([@B99]). A truncated dermaseptin derivative was found to exert anti-*P. falciparum* activity within less than 1 min after exposure, involving permeabilization of the host cell membrane ([@B13]). In order to decrease hemolytic activity of dermaseptins, aminoheptanoyl derivatives were synthesized; a screening against *P. falciparum* revealed higher activity for the more hydrophobic dermaseptin derivatives, some of which showing significant selectivity between antiplasmodial activity versus hemolytic activity ([@B46]; [@B53]).

Following discovery of antiplasmodial activity of the 28-residue AMP dermaseptin S4 ([@B57]), a derived 13-residue AMP, K4-S4(1-13), was found to display considerable *in vitro* efficacy on *P. falciparum* ([@B74]). The antiplasmodial action of K4-S4(1-13) was fast and shown to be mediated by permeabilization of host cell plasma membrane. Although K4-S4(1-13) was less hemolytic to healthy RBC than to *Pf*RBC, selectivity was not high enough and turned evident the necessity to develop additional derivatives active on parasites but with minimal threat to normal erythrocytes. Recently, acyl derivatives of K4-S4(1-13) were shown to have increased antiplasmodial activity, but the most potent of them was still significantly hemolytic ([@B39]).

### Antimalarial peptides from insect vectors of parasitic diseases

Antimicrobial peptides of insect origin have been found which display antimalarial properties. Drosomycins, isolated from *Drosophila melanogaster*, are an example of insect antimalarial peptides. Drosomycins were tested against development of *P. berghei* ANKA gametocytes, with drosomycin-2 showing 30% inhibition at 20 μM, whereas prototype-peptide drosomycin showed over 70% inhibition at that same concentration ([@B128]).

The most interesting source of antimalarial AMP concerns insects that are themselves the vectors of parasitic diseases, like anopheline mosquitoes, responsible for malaria transmission. It seems logical that such insects need to be equipped with a considerable defense system against the parasites they carry. In *Anopheles* mosquitoes, there are different known protection mechanisms, such as (i) upregulation of NO synthase, (ii) melanotic encapsulation in refractory mosquitoes that inhibit parasite development ([@B32]; [@B131]), and production of AMP that might play an important role in refractoriness. In the major vector of *P. falciparum* in sub-Saharan Africa, *A. gambiae*, defensin, cecropin, and gambicin AMP have been found ([@B134]; [@B17]; [@B71]).

The *A. gambiae* cecropin gene is mainly expressed in the mosquito midgut in hemocyte-like cells, and its levels are significantly raised within 2 h of infection ([@B134]). The activity of the *A. gambiae* cecropin against *Plasmodium* was studied by creating transgenic mosquitoes with cecA expression under the control of the *Aedes aegypti* carboxypeptidase promotor. The number of oocysts was reduced by 60% compared to the non-transgenic mosquitoes ([@B71]).

Gambicin, extracted from two *A. gambiae* cell lines, is an immune-induced peptide predominantly expressed in the anterior midgut compartment, thorax, and abdomen. The mature gambicin peptide is active against Gram-positive and Gram-negative bacteria, filamentous fungi, and *P. berghei* ookinetes ([@B135]).

Other mosquito vectors, such as *A. aegypti*, responsible for transmission of dengue and yellow fever viruses, produce AMP with antimalarial activity. *A. aegypti* releases three 40-AA long defensins (Def A to C) and cecropin A in response to bacterial infections ([@B92], [@B93]). In transgenic *A. aegypti* mosquitoes with co-overexpression of *A. aegypti* cecropin A and defensin A, *P. gallinaceum* oocyst proliferation was significantly inhibited as compared to wildtype mosquitoes ([@B91]; [@B73]).

The strategy to produce transgenic mosquitoes that heterologously express AMP in order to interrupt *Plasmodium* transmission was also tested for scorpine, an AMP from the venom of *Pandinus imperator* scorpions. Scorpine belongs to a group of ion channel blockers with high activity against *P. berghei* ANKA gametes and ookinetes (ED~50~ of 10 and 0.7 μM, respectively; [@B33]) that was shown to disrupt the sporogonic development of *P. berghei*. The scorpine gene was introduced into a vector for generation of transgenic flies resistant to infection by *Plasmodia*. The final aim of this work was to incorporate this gene under the promoter of proteolytic enzymes of the mosquito digestive tract, for synthesis and release of toxic peptide(s) into the stomach of freshly fed mosquitoes potentially carrying *Plasmodium* gametes; the presence of recombinant scorpine could be confirmed in transgenic *A. gambiae* cell supernatants ([@B107]). At low concentrations, recombinant scorpine reduced the number of ookinetes formed after mosquito feeding on *P. berghei*-infected mouse blood. Scorpine had highest effects (98% inhibition) when added during gamete formation and fertilization ([@B24]). In view of this, strategies to deliver AMP into the mosquitoes to interrupt the sporogonic cycle are relevant; one such strategy has been reported that uses symbiotic bacteria that live in the mosquito's midgut: the transgenetic symbiont *Pantoea agglomerans*, expressing recombinant AMP Shiva-1 and scorpine, completely inhibited *P. falciparum* sporogonic cycle ([@B137]).

### Circular AMP with antimalarial properties

There is a significant number of cyclic AMP and derived macrocycles that have shown antimalarial properties. The potentially large, but structurally often well-defined conformational space sampled, combined with the variety of AA, renders cyclic peptides ideally suited to interact with many receptors or to interfere with protein/protein interactions ([@B70]; [@B58]). In this context, cyclosporin A (CsA, 1 in **Figure [2](#F2){ref-type="fig"}**) is a well-characterized immunosuppressant hydrophobic peptide ([@B21]) that was earlier found to have antimalarial activity against *P. berghei* and *P. yoelii* rodent malaria and on cultured *P. berghei, P. falciparum,* and *P. vivax* parasites ([@B102]). More recently, nine CsA-resistant *P. falciparum* clones were isolated, of which three had lesions in cyclophilin genes and two in calcineurin-subunit genes ([@B76]). The two cyclophilins affected had been identified as cyclosporin-binding proteins in *P. falciparum* ([@B53]), but CsA may also have other targets in *Plasmodia*, since, it has a number of different known targets including the mammalian P-glycoprotein transporter. In agreement with this hypothesis, sequence polymorphisms in (and possibly expression levels of) a *P. falciparum* P-glycoprotein homolog were found to affect susceptibility to CsA ([@B54]).

![**Circular peptides with antimalarial activity.** Full molecular structure is shown. Amino acid labeling, with the corresponding three-letter code, has been added where applicable: **Abu**, 2-aminobutyric acid; **Ala**, [L]{.smallcaps}-alanine; **D-Ala**, [D]{.smallcaps}-alanine; **Dha**, dehydroalanine; **Gly**, glycine; **Ile**, [L]{.smallcaps}-isoleucine; **Phe**, [L]{.smallcaps}-phenylalanine; **Thr**, [L]{.smallcaps}-threonine; **Val**, [L]{.smallcaps}-valine; **MeGly**, *[N]{.smallcaps}*-methylglycine \[also known as sarcosine (Sar)\]; **MeLeu**, *[N]{.smallcaps}*-methylleucine; **MeVal**, *[N]{.smallcaps}*-methylvaline. Uncommon amino acid residues or their analogs not possessing any internationally approved abbreviation were kept unlabeled.](fphar-05-00275-g002){#F2}

Thiostrepton (2 in **Figure [2](#F2){ref-type="fig"}**), a cyclic thiopeptide, has reported IC~50~ ranging from 1.8 to 17 μM against parasite growth and protein synthesis of *P. falciparum*, though this is suggested to be an overestimate since solubility of the compound in culture medium is poor ([@B31]; [@B100]). IC~50~ values for thiostrepton derivatives were 0.77 μM and above against *P. falciparum* ([@B118]), and other thiopeptides were described as displaying nanomolar IC~50~ against organellar protein synthesis in the same strain: micrococcin (3 nM), GE2270A (300 nM), and amythiamicin A (10 nM; [@B30]).

Most recently, three new macro-heterocyclic AMP, balgacyclamides A--C, were isolated from *Microcystis aeruginosa* EAWAG 251 and thoroughly characterized. Balgacyclamides A (3 in **Figure [2](#F2){ref-type="fig"}**) and B (4 in **Figure [2](#F2){ref-type="fig"}**) were evaluated for their antiparasitic activity and found to display micromolar IC~50~ activity against the chloroquine-resistant strain K1 of *P. falciparum* (9.0 and 8.2 μM, respectively) with good selectivity compared to their cytotoxicity ([@B106]).

Another recent report on a cyclic antimalarial peptide concerns the Gly-rich cyclic octapeptide pohlianin C (5 in **Figure [2](#F2){ref-type="fig"}**), whose synthesis provided confirmation of the structure of this natural product. Evaluation against *P. falciparum* showed moderate antiplasmodial activity, consistent with data obtained from the natural sample. In addition, the synthesis of three analogs revealed that the antiplasmodial activity of pohlianin C can be preserved or increased with simplified structures ([@B79]).

### Other synthetic antimalarial AMP: from NK-2 to IDR-1018

NK-2 was one of the first synthetic AMP found to have anti-parasitic properties. NK-2 is a shortened version of the mammalian protein NK-lysin, comprising its residues 39--65, and long known to display lytic activity against the fungal pathogen *Candida albicans* and a variety of Gram-positive and Gram-negative bacteria, while exhibits virtually no hemolytic or cytotoxic activity against human cells ([@B3]). In a study aimed at determining the antimicrobial spectrum of both NK-lysin and NK-2, activity against the protozoan parasite *Trypanosoma cruzi* was observed ([@B64]). Later, NK-2 was found to be hemolytic to *Pf*RBC above ∼1 μM, while harmless for healthy RBC up to 10 μM, along with evidence that parasite membrane also suffered permeabilization at 5 and 10 μM. The selective lytic activity of NK-2 on *Pf*RBC was further demonstrated by observation that fluorescently labeled NK-2 binds to infected erythrocytes and to parasites, but not to healthy erythrocytes ([@B56]).

Another synthetic AMP with antimalarial activity is D-HALO-rev. This design peptide possesses 26 AA with an even distribution of hydrophobic and charged residues, including non-proteinogenic ornithine (O, Orn), a Lys homolog. D-HALO-rev shows an IC~50~ value of 0.1 μM against erythrocytic stages of *P. falciparum*, being able to penetrate *Pf*RBC at sublytic concentrations and kill intraerythrocytic parasites ([@B98]). Similar results were obtained for an analog resulting from incorporation of Pro, Phe, and D-AA residues (D-Halo-P8F-rev), which showed reduced toxicity toward healthy RBC and fibroblasts ([@B98]).

A further step forward in this field was recent disclosure of the ability of synthetic peptide IDR-1018 to provide protection against cerebral malaria ([@B1]). IDR-1018 is a 12-residue innate defense regulator analog of bactenecin, a cathelicidine from bovine neutrophils. It putatively owes its action to translocation across cell membrane and impairment of an intracellular target ([@B144]). IDR-1018 was selected for screening in cerebral malaria given its anti-inflammatory capabilities and low toxicity, and found to protect 56% of infected mice from cerebral malaria after prophylactic intravenous administration. When combined with the antimalarial pyrimethamine-chloroquine medicine, IDR-1018 boosted protection from cerebral malaria in 41--68% of infected mice ([@B1]).

PROMISES AND PITFALLS OF PEPTIDE ANTIMALARIALS: FROM CONVENTIONAL PHARMACEUTICAL TO BIOTECHNOLOGICAL APPROACHES
---------------------------------------------------------------------------------------------------------------

Examples of peptide drug candidates entering clinical trials remain scarce, as compared to those of small molecular drug candidates; despite a few such peptides display antimalarial activity (pexiganan in phase III, omiganan and OP-145 in phase 2, and NVB302 in phase I), their involvement in clinical trials is directed to disorders other than malaria ([@B50]). This is mainly due to the traditionally cautious attitude of pharma companies toward peptide-based drugs, given that:

1.  • peptides seldom are orally bioavailable given their usually high molecular weight, extensive enzymatic degradation (proteolysis) and binding to plasma proteins;

2.  • peptide production costs are high and synthesis scale-up is not easy, which will result in medicines too expensive, especially if targeted at low-income countries.

Therefore, until recent years, pharma companies have mostly put their bets on small drug candidates, with molecular weights tipically below 500 Da and oral bioavailability, leaving much larger biomolecule-based candidates put aside, as molecules with over 5000 Da are not orally bioavailable, among other limitations. However, small drugs often suffer from reduced selectivity, leading to unwanted off-target side effects; in turn, peptides and proteins are usually characterized by an extraordinary specificity for their targets, which may largely compensate for their low bioavailability, poor permeability and susceptibility to metabolic inactivation ([@B38]).

In the particular case of malaria, from World War II to the present, a huge plethora of small molecules nicely obeying the Lipinski's rule of 5 for orally bioavailable drugs ([@B89]) has been continuously feeding the antimalarial drug pipeline ([@B127]). Nonetheless, control of the disease remains out of reach, especially due to toxicity and resistance issues ([@B141]). Moreover, Lipinski's rule applies only to drug absorption by passive diffusion through cell membranes, i.e., it is not predictive for compounds actively transported by transmembranar proteins ([@B85]). Altogether, this emphasizes the need for highly specific antimalarials, preferably with no or reduced propensity to elicit parasite resistance, and also that unconventional drugs, like peptides, may eventually fill such need, provided suitable strategies to overcome some challenges posed by peptide drugs are found. Fortunately, the 21st century emerged along with the first evidences of a paradigm shift in this field: between 2011 and 2012, nineteen peptide drugs were approved in the US, and the remarkable expansion of peptide therapeutics development in the late 1990s and 2000s led to an unprecedented number of marketing approvals in 2012, while providing a robust pipeline that should deliver numerous approvals during the remainder of the 2010s; in the US, annual sales of peptide drugs exceed 13 bilion dollars, representing 1.5% of global drug sales. In Europe, Germany and the UK account for 63% of the peptide therapeutics market, with France, Italy, Scandinavia, and Spain making up the rest of the major European salers in this area ([@B69]).

In addition to the above, peptide and protein biotechnology continues evolving at full speed, with the most prominent example today being that of therapeutic antibodies ([@B84]). Other biotechnological approaches include, e.g., bioactive peptide grafting onto suitable biocompatible carriers to enhance peptide bioavailability at the site of action ([@B34]; [@B82],[@B83]; [@B95]), or development of long-acting release forms of peptides such as somatostatin analogs through encapsulation in biodegradable polymers requiring injection only at extended intervals to raise patient's compliance ([@B4]). Genetic engineering and recombinant biotechnology are changing pharma's perspective toward peptide therapeutics, as genetically engineered proteins offered a window to previously untreatable medical conditions that convinced this industry to conform with the need to develop drugs that could not be administered through the oral route; it also motivated an intense search for alternative (to injection) drug delivery platforms to meet patient's acceptability, and offers an useful alternative to chemical production of large (\>40 AA) peptides, whose synthesis is challenging and expensive, even at low scale; hence, recombinant biotechnology will play an increasingly important role in peptide manufacturing mainly due to quantity requirements ([@B81]). Still, biotechnology will complement, and not replace, chemical peptide synthesis in the production of peptide therapeutics: cost of large-scale peptide chemical synthesis, in particular through the most popular solid-phase procedures based on Fmoc-chemistry, has significantly decreased over the past 15 years, mainly due to technological evolution of automated synthesizers and chromatographic systems; moreover, many highly specific and potent peptide therapeutics require daily doses of only a few micrograms; furthermore, when applicable, chemical peptide synthesis is more easily scalable for manufacturing at up to a multi-10 kg or 100-kg scale, and is less demanding in terms of process development, and less personnel intensive in terms of production, quality assurance and regulatory affairs; last, but not least, chemical approaches are far superior to biotechnological ones regarding flexibility in the design of analogs requiring unnatural amino acids or non-proteogenic building blocks ([@B81]).

In summary, peptide therapeutics are reaching a maturity level that emphasizes their potential interest against a wide diversity of medical challenges. While, about half of the peptides in clinical trials target indications in oncology, metabolic, cardiovascular and infectious diseases, the total range of therapeutic areas addressed encompasses a wide assortment of medical disorders from endocrinological lesions through to pain and hematology ([@B69]). In the particular case of malaria, development of peptide therapeutics is still at its earliest infancy, but several cutting-edge approaches to antimalarial peptides are emerging today. One recent example followed demonstration that *Pf*SERA5 plays an important role in parasite development; in this study, a number of peptides from the *N*- and *C*-terminal regions of *Pf*SERA5 active domain was synthesized and evaluated as antiplasmodials. These peptides reduced activity of the recombinant enzyme and co-localized with *Pf*SERA5 within the parasite, thereby indicating the specific inhibition of *Pf*SERA5 activity. Such results reinforce the role of *Pf*SERA5 for the intraerythrocytic development of malaria parasites and unveil the relevance of this enzyme as target for new peptide antimalarials ([@B68]). In view of this, and considering the recent unveiling of the *P. falciparum* genome ([@B18]), we can only expect the future to confirm that a new class of antimalarial drugs, based on AMP, will rise.

CONCLUDING REMARKS
==================

This review highlights that peptides are being put forward as one potential novel class of antimalarial drugs. A range of AMP exhibit antimalarial activity on malarial parasites in their blood or mosquito stages or both. Some peptides naturally occurring in mosquitoes affect the parasites transmitted by those insect vectors, but it has been difficult to determine the magnitude of their effects in the natural setting. However, this field of research is a recent one, and more systematic studies are needed to identify the structural variants that are most potent and selective on cultured parasites and to test them *in vivo*. Better understanding of mechanisms of action would help to guide the design of new peptides and the development of *in vitro* assays with which to compare their target-binding affinities. Some antimalarial peptides are believed to act selectively on infected erythrocyte and/or intraerythrocytic parasite membranes, in which case the appropriate model membrane systems are required. This means that another well-known family of MAP, besides AMP, may soon gain also relevance in antimalarial approaches: that of CPP. These can translocate into cells without causing membrane damage, therefore being useful carriers for therapeutic cargoes to treat various conditions ([@B40]). Membrane-active AMP and CPP show significant similarities in charge, structure, and initial steps of interactions with membranes; moreover, CPP are being identified with antimalarial activity *per se*, e.g., TP10 that has broad-spectrum activity against both blood and mosquito stages of *P. falciparum* ([@B5]). In conclusion, MAP seem to be paving the way toward establishment of useful peptide-based drugs against parasitic infections.
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